SARS-CoV-2: Virology, epidemiology, immunology and vaccine development. (July 2020)

• Record Type: Journal Article
• Authors: Baay, Marc; Lina, Bruno; Fontanet, Arnaud; Marchant, Arnaud; Saville, Melanie; Sabot, Philippe; Duclos, Philippe; Vandeputte, Joris; Neels, Pieter
• Is Part Of: Biologicals. Volume 66(2020)
• Page Start: 35
• Page End: 40
• Publication Date: 2020-07
• Subjects: SARS-CoV-2 -- Virology -- Epidemiology -- Immunology -- Vaccine development; Biological products -- Standards -- Periodicals; Biological Products -- Periodicals; Biological Products -- standards -- Periodicals; Produits biologiques -- Normes -- Périodiques; Biological products -- Standards; Periodicals; 615.37
• DOI: 10.1016/j.biologicals.2020.06.005
• Languages: English
• ISSNs: 1045-1056

Abstract

Abstract: This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2. Highlights: In SARS-CoV-2, genetic diversity exists but has limited impact on antigenicity. Second and possibly third SARS-CoV-2 waves are expected, only to be controlled with safe and effective vaccines. Immunopathology plays a role in severe Covid-19, with a role for macrophages, T lymphocytes and potentially antibodies. Normally taking many years, under the outbreak paradigm, the goal is to achieve vaccine development within 12–18 months.